UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.688

Sortiert nach

Na+/Taurocholate Cotransporting Polypeptide and Apical Sodium-Dependent Bile Acid Transporter Are Involved in the Disposition of Perfluoroalkyl Sulfonates in Humans and Rats

Toxicological sciences, 2015-08, Vol.146 (2), p.363-373

2015

Link zum Volltext

Verfügbarkeit prüfen

Human and nonclinical disposition of [14C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infection

Xenobiotica, 2022-11, Vol.52 (9-11), p.973-985

2022

Link zum Volltext

Verfügbarkeit prüfen

Mechanistic Basis of Cabotegravir-Glucuronide Disposition in Humans

The Journal of pharmacology and experimental therapeutics, 2019-08, Vol.370 (2), p.269

2019

Link zum Volltext

Verfügbarkeit prüfen

Morphine metabolism, transport and brain disposition

Metabolic brain disease, 2012-03, Vol.27 (1), p.1-5

2012

Link zum Volltext

Verfügbarkeit prüfen

Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N -Acetylgalactosamine-Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans

The Journal of pharmacology and experimental therapeutics, 2021-11, Vol.379 (2), p.134

2021

Link zum Volltext

Verfügbarkeit prüfen

Organic Anion Transporting Polypeptides Contribute to the Disposition of Perfluoroalkyl Acids in Humans and Rats

Toxicological sciences, 2017-03, Vol.156 (1), p.84-95

2017

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and Disposition of Contezolid in Humans: Resolution of a Disproportionate Human Metabolite for Clinical Development

Antimicrobial agents and chemotherapy, 2021-10, Vol.65 (11), p.e0040921

2021

Link zum Volltext

Verfügbarkeit prüfen

Metabolism and disposition of [14C]tivantinib after oral administration to humans, dogs and rats

Xenobiotica, 2014-11, Vol.44 (11), p.996-1008

2014

Link zum Volltext

Verfügbarkeit prüfen

Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans

Acta pharmacologica Sinica, 2022-02, Vol.43 (2), p.494-503

2022

Link zum Volltext

Verfügbarkeit prüfen

Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human

Journal of pharmacokinetics and pharmacodynamics, 2012-02, Vol.39 (1), p.67-86

2012

Link zum Volltext

Verfügbarkeit prüfen

Metabolic disposition of the anti-cancer agent [14C]laromustine in male rats

Xenobiotica, 2015-08, Vol.45 (8), p.711-721

2015

Link zum Volltext

Verfügbarkeit prüfen

A “middle‐out approach” for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) models

CPT: pharmacometrics and systems pharmacology, 2023-03, Vol.12 (3), p.346-359

2023

Link zum Volltext

Verfügbarkeit prüfen

Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin‐drug interactions

Phytotherapy research, 2021-06, Vol.35 (6), p.3286-3297

2021

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species

Acta pharmacologica Sinica, 2018-06, Vol.39 (6), p.1048-1063

2018

Link zum Volltext

Verfügbarkeit prüfen

A translational platform PBPK model for antibody disposition in the brain

Journal of pharmacokinetics and pharmacodynamics, 2019-08, Vol.46 (4), p.319-338

2019

Link zum Volltext

Verfügbarkeit prüfen

Sinusoidal Organic Anion-Transporting Polypeptide 1B1/1B3 and Bile Canalicular Multidrug Resistance-Associated Protein 2 Play an Essential Role in the Hepatobiliary Disposition of a Synthetic Cyclic Dinucleotide (STING Agonist)

The AAPS journal, 2022-09, Vol.24 (6), p.99, Article 99

2022

Link zum Volltext

Verfügbarkeit prüfen

Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor

European journal of pharmaceutical sciences, 2019-08, Vol.136, p.104938, Article 104938

2019

Link zum Volltext

Verfügbarkeit prüfen

2,4,6-Tribromophenol Disposition and Kinetics in Rodents: Effects of Dose, Route, Sex, and Species

Toxicological sciences, 2019-05, Vol.169 (1), p.167-179

2019

Link zum Volltext

Verfügbarkeit prüfen

In vitro and in vivo pharmacokinetics, disposition, and drug-drug interaction potential of tinengotinib (TT-00420), a promising investigational drug for treatment of cholangiocarcinoma and other solid tumors

European journal of pharmaceutical sciences, 2024-01, Vol.192, p.106658-106658, Article 106658

2024

Link zum Volltext

Verfügbarkeit prüfen

Mechanistic pharmacokinetics and pharmacodynamics of GalNAc-siRNA: Translational model involving competitive receptor-mediated disposition and RISC-dependent gene silencing applied to givosiran

Journal of pharmaceutical sciences, 2024-01, Vol.113 (1), p.176-190

2024

Link zum Volltext

Verfügbarkeit prüfen

Metabolism and disposition of corylifol A from Psoralea corylifolia: metabolite mapping, isozyme contribution, species differences and identification of efflux transporters for corylifol A-O-glucuronide in HeLa1A1 cells

Xenobiotica, 2020-08, Vol.50 (8), p.997-1008

2020

Link zum Volltext

Verfügbarkeit prüfen

Metabolism and disposition of the SGLT2 inhibitor bexagliflozin in rats, monkeys and humans

Xenobiotica, 2020-05, Vol.50 (5), p.559-569

2020

Link zum Volltext

Verfügbarkeit prüfen

Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes

The Journal of pharmacology and experimental therapeutics, 2013-12, Vol.347 (3), p.727

2013

Link zum Volltext

Verfügbarkeit prüfen

Metabolism and Disposition of the Novel Oral Factor XIa Inhibitor Asundexian in Rats and in Humans

European journal of drug metabolism and pharmacokinetics, 2023-07, Vol.48 (4), p.411-425

2023

Link zum Volltext

Verfügbarkeit prüfen

Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation

The Journal of pharmacology and experimental therapeutics, 2013-01, Vol.344 (1), p.196

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 2.688

Suche als RSS-Feed

Aktive Filter

KollektionNUS Single-Journal Subscriptions

SpracheChinesisch

SpracheTürkisch

KollektionMEDLINE

ThemaHumans

ThemaRats

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.512)
Mit Volltextzugriff
(2.313)

Publikationsform

Artikel
(2.685)
Buchkapitel
(3)

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

13 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Na+/Taurocholate Cotransporting Polypeptide and Apical Sodium-Dependent Bile Acid Transporter Are Involved in the Disposition of Perfluoroalkyl Sulfonates in Humans and Rats

Human and nonclinical disposition of [14C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infection

Mechanistic Basis of Cabotegravir-Glucuronide Disposition in Humans

Morphine metabolism, transport and brain disposition

Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N -Acetylgalactosamine-Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans

Organic Anion Transporting Polypeptides Contribute to the Disposition of Perfluoroalkyl Acids in Humans and Rats

Pharmacokinetics and Disposition of Contezolid in Humans: Resolution of a Disproportionate Human Metabolite for Clinical Development

Metabolism and disposition of [14C]tivantinib after oral administration to humans, dogs and rats

Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans

Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human

Metabolic disposition of the anti-cancer agent [14C]laromustine in male rats

A “middle‐out approach” for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) models

Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin‐drug interactions

Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species

A translational platform PBPK model for antibody disposition in the brain

Sinusoidal Organic Anion-Transporting Polypeptide 1B1/1B3 and Bile Canalicular Multidrug Resistance-Associated Protein 2 Play an Essential Role in the Hepatobiliary Disposition of a Synthetic Cyclic Dinucleotide (STING Agonist)

Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor

2,4,6-Tribromophenol Disposition and Kinetics in Rodents: Effects of Dose, Route, Sex, and Species

In vitro and in vivo pharmacokinetics, disposition, and drug-drug interaction potential of tinengotinib (TT-00420), a promising investigational drug for treatment of cholangiocarcinoma and other solid tumors

Mechanistic pharmacokinetics and pharmacodynamics of GalNAc-siRNA: Translational model involving competitive receptor-mediated disposition and RISC-dependent gene silencing applied to givosiran

Metabolism and disposition of corylifol A from Psoralea corylifolia: metabolite mapping, isozyme contribution, species differences and identification of efflux transporters for corylifol A-O-glucuronide in HeLa1A1 cells

Metabolism and disposition of the SGLT2 inhibitor bexagliflozin in rats, monkeys and humans

Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes

Metabolism and Disposition of the Novel Oral Factor XIa Inhibitor Asundexian in Rats and in Humans

Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation

Aktive Filter

Suchergebnisse filtern